Relative cost of multidrug-resistant TB medicines in Europe
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
107 0
SM ISO690:2012
GUNTHER, Gunar, GUGLIELMETTI, Lorenzo, LEU, Claude, VAN LETH, Frank, LANGE, Christoph G., HAFIZI, Hasan, KHACHATRYAN, Naira, AROYAN, Harut, KABASAKALYAN, Eduard E., KNAPPIK, Michael, SKRAHINA, Alena, KLIMUK, Dzmitry, NOI, Autori, CHESOV, Dumitru. Relative cost of multidrug-resistant TB medicines in Europe. In: International Journal of Tuberculosis and Lung Disease, 2023, vol. 27, pp. 341-344. ISSN 1027-3719. DOI: https://doi.org/10.5588/ijtld.23.0026
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
International Journal of Tuberculosis and Lung Disease
Volumul 27 / 2023 / ISSN 1027-3719 /ISSNe 1815-7920

Relative cost of multidrug-resistant TB medicines in Europe

DOI:https://doi.org/10.5588/ijtld.23.0026

Pag. 341-344

Gunther Gunar1, Guglielmetti Lorenzo2, Leu Claude1, van Leth Frank3, Lange Christoph G.4567, Hafizi Hasan8, Khachatryan Naira9, Aroyan Harut10, Kabasakalyan Eduard E.11, Knappik Michael12, Skrahina Alena13, Klimuk Dzmitry13, Noi Autori, Chesov Dumitru14
 
1 University of Bern,
2 Sorbonne University,
3 Vrije University Amsterdam,
4 Research Center Borstel,
5 German Centre for Infection Research (DZIF), Partner Site Hamburg-Luebeck-Borstel-Riems,
6 University of Lübeck,
7 Baylor College of Medicine,
8 University of Tirana,
9 American University of Armenia, Erevan,
10 Armenian Ministry of Health, Yerevan,
11 National Centre of Pulmonology, Abovyan,
12 Klinik Penzing, Vienna,
13 Republican Scientific and Practical Centre of Pulmonology and Tuberculosis, Ministry of Health, Minsk,
14 ”Nicolae Testemițanu” State University of Medicine and Pharmacy
 
 
Disponibil în IBN: 6 noiembrie 2023


Cuvinte-cheie
bedaquiline, Clofazimine, cycloserine, ethambutol, isoniazid, levofloxacin, linezolid, moxifloxacin, pyrazinamide, rifampicin, terizidone, tuberculostatic agent, tuberculostatic agent